FY2023 · ended Dec 31, 2023 · Revenue $70,000, -96.0% YoY · Filed Apr 15, 2025
Oncotelic Therapeutics, Inc. (OTLC) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$70,000
-96.0% vs prior year
Net income (TTM)
$247.52M
+6404.1% vs year-ago TTM
Operating cash flow (TTM)
$-1.52M
-182.2% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$0.56
Dividend per share
None
Shares outstanding
444.20M
+8.8% vs prior year
Net cash
$-2.33M
FY 2024
Operating margin
-9497.2%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OTLC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aguora Hills, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 908259
- Former names
- MATEON THERAPEUTICS INC (until Mar 26, 2021); OXIGENE INC (until Jun 3, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $70,000 | — | — |
| Operating income | -$3.2M | -$3.6M | -$6.6M | -$9.7M | -$9.1M |
| Net income | $249.3M | -$4.5M | -$7.9M | $5.1M | -$9.4M |
| Diluted EPS | $0.59 | — | -$0.02 | $0.01 | — |
| Operating cash flow | -$1.4M | -$740,277 | -$1.3M | -$1.5M | -$4.4M |
| Total assets | $393.1M | $26.7M | $30.0M | $36.1M | $23.6M |
| Total liabilities | $131.4M | $19.2M | $18.4M | — | — |
| Stockholders' equity | $262.8M | $8.3M | $12.1M | $19.4M | $8.0M |
| Cash and investments | $88,857 | $86,128 | — | — | — |
| Total debt | — | $2.4M | $1.8M | $390,050 | $359,262 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 7, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Jul 14, 2026 | Jul 10, 2026 |
All 1007 Oncotelic Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.